

## Asthma Treatment

---

Reference Number: F4603  
Date of Response: 20<sup>th</sup> May 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### **Request and Royal Devon's Eastern FOI Office Response**

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab: **81 Patients**
- Omalizumab: **87 Patients**
- Reslizumab: **\*<5**
- Mepolizumab: **25 Patients**

**Data relating to less than 5 individuals is represented above using \*<5.**

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6-11: **\*<5**
- Age 12-17: **\*<5**
- Age 18 and above: **188 Patients**

**Data relating to less than 5 individuals is represented above using \*<5.**

Q3. How many patients have been treated in the last four months with Dupilumab for Asthma ONLY?

**We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. therefore this would breach Caldicott principles and principle One of the GDPR.**

**This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.**